ArticleClinical, cosmetic and investigational dermatology2025
Prevalence of Livedoid Vasculopathy Among Patients with Connective Tissue Diseases and Its Association with Thrombophilic Factors: A Hospital-Based Retrospective Cohort (2014-2021).
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Livedoid vasculopathy is a rare, chronic thrombo-occlusive disorder that primarily affects the lower extremities, causing painful ulcerative lesions. Despite its clinical significance, the prevalence and demographic characteristics of LV, particularly among patients with connective tissue diseases, remain underexplored. This study aims to investigate the prevalence of LV among patients diagnosed with CTDs, providing insight into potential epidemiological patterns. Methods: The study was a retrospective cohort study conducted at Mass General Brigham (MGB), a healthcare system in Greater Boston, Massachusetts, from January 1, 2014, to June 1, 2021. Data extraction was facilitated through the Mass General Brigham Enterprise Data Warehouse utilizing the Research Patient Data Registry (RPDR) system. Data extraction includes age, gender, race and autoimmune diseases associated with LV. SPSS v 29 was used for data analysis. Results: We reviewed 1730 charts; 108 patients met criteria for LV. Prevalence is reported within the screened cohort (108/1730 = 6.2%). For system context, we also report a hospital-system registered prevalence of 0.0018% (108/6,000,000) based on the RPDR population. The majority of patients were female (74.07%). The mean age of the patients with LV was 44.87 ± 8.24 years. The racial composition was white (84.25%). Among the 17 patients with autoimmune diseases, females were more represented (82.35%). Systemic lupus erythematosus was the predominant condition, affecting 58.82% of these patients. Positive results for phospholipid antibodies were found in 57.40% of patients, with a p-value of 0.065. For anticardiolipin antibodies, p-value 0.095. Hyperhomocystenemia, p-value of 0.952. Activated C resistance, p-value of 0.088. Conclusion: In this cohort of patients with connective tissue diseases, livedoid vasculopathy was observed more often in women and in middle-aged adults, and it frequently co-occurred with autoimmune conditions, particularly systemic lupus erythematosus. However, none of the between-group comparisons or serological associations reached statistical significance. These results should be interpreted as non-confirmatory trends and require validation in larger, adequately powered studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.